Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CXCL6 Biologics Sequence Review Report 2026: C-X-C motif chemokine 6 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL5 Biologics Sequence Review Report 2026: C-X-C motif chemokine 5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL17 Biologics Sequence Review Report 2026: C-X-C motif chemokine 17 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL16 Biologics Sequence Review Report 2026: C-X-C motif chemokine 16 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CDR1 Biologics Sequence Review Report 2026: Cerebellar degeneration-related antigen 1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CDR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD99L2 Biologics Sequence Review Report 2026: CD99 antigen-like protein 2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD99L2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD9 Biologics Sequence Review Report 2026: CD9 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD8B2 Biologics Sequence Review Report 2026: T-cell surface glycoprotein CD8 beta-2 chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD8B2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD83 Biologics Sequence Review Report 2026: CD83 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD83 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD82 Biologics Sequence Review Report 2026: CD82 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD82 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD81 Biologics Sequence Review Report 2026: CD81 antigen Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD81 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CD74 Biologics Sequence Review Report 2026: HLA class II histocompatibility antigen gamma chain Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CD74 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
90
91
92
93
94
>>
1503
>